P30 CANCER CENTER SUPPORT GRANT (CCSG) ELECTRONIC DATA (eData) GUIDE v3.1.4

National Institute of Health / DHHS

National Cancer Institute

Office of Cancer Centers

9609 Medical Center Drive

Rockville, MD 20850

https://cancercenters.cancer.gov/

Table of Contents

INTRODUCTION

BACKGROUND

The Office of Cancer Centers (OCC) of the National Cancer Institute (NCI) is responsible for overseeing a portfolio of Cancer Center Support Grants (CCSG) that support cancer research at NCI-Designated Cancer Centers across the U.S. The centers program was established by the 1971 National Cancer Act and serves as a major platform for advancing NCI initiatives.

The CCSG Data Tables (DTs) itemize the center's formal research programs, shared resources, base of funded research projects, patient information, clinical research protocols, and current and requested budgets. The primary reason for standardized DTs is to ensure consistency and thoroughness during the peer review of competing applications. Additionally, the DTs are used to assess center progress, generate reports, and produce benchmark data on the center's program.

Each year, 60 days before the award anniversary date, the centers are required to submit an electronic copy of DT1-4 in Excel format directly to the OCC at ccsgdata@mail.nih.gov. Per NIH policy, Type 2 applications serve as the progress report for the fiscal year in which the application is newly funded. While it is not required to submit a separate RPPR 60 days before the start date of the newly funded award, eData 1-4 must still be submitted at that time.

The data submitted by all NCI-Designated Cancer Centers are verified for consistency and imported into the OCC SQL-Server database. In addition, aggregate DTs, detailed data, and reports are presented on the OCC website: http://cancercenters.cancer.gov.

PURPOSE

The purpose of the CCSG Electronic Data Guide, herein referred to as eData Guide, is to present a description and standard format for the submission of electronic data. This format will allow centers' data to be processed and shared in a uniform and consistent manner. The eData Guide seeks to accomplish the following:

- Facilitate data standardization
- Streamline the data-importing process
- Improve data quality and analysis
- Simplify data management and reporting

This eData Guide is meant as a specific guide for the eData submission and describes each of the data table's field columns at a granular level with significant technical detail. It identifies each data column, definition, type, and usage; it also includes an example(s) for each of the data tables. The CCSG Data Guide should be consulted to derive background information regarding each DT's purpose and prepare the DTs that accompany Type 1 and Type 2 competitive applications. DT5 is not required to be submitted electronically; therefore, it is excluded from this document.

OCC DATABASE

As a step toward improving web interactivity, the existing OCC website has been redesigned to a more dynamic or database-driven website. The centralized database that supports this enhanced website application is where all the tables, views, stored procedures, user-defined functions, and triggers are created.

Within the database, tables are commonly referred to as “entities.” Data columns (fields) are commonly referred to as “attributes” for a table. The underscore character will not be used within table column names. Furthermore, all tables in the OCC databases will begin with an uppercase letter followed by a series of upper and lowercase letters. Meaningful table names have been chosen to identify the overall purpose of each database table (e.g., P30Partner).

Each data column in the table has a data type, which defines which kind of data should be stored in a column.

Please note the **distinction between a blank space and a NULL value**; a blank space is a character string while a NULL value is an unknown value. If the data is not available or applicable, use NULL by leaving the column empty.

Table 1 provides an overview of data types that are used in the OCC database.

TABLE 1: OVERVIEW OF DATA TYPES

DATA TYPE	ABBR	SYNTAX	VALID ENTRY	DESCRIPTION
Character	Char	Char(*n*)	A character or NULL value	Fixed-length, non-Unicode string data. n defines the string length and must be a value from 1 through 8,000. It is used for data that are a mixture of numbers and letters (alphanumeric data).
Datetime	-	DateTime	Date/time or NULL value	Stores exact date/time values
Varchar [(n | max)]	-	Varchar(*n*), or Varchar (max)	A character string	Variable-length, standard character string data. n defines the string length and can be a value from 1 through 8,000.
Float	-	Float	Numeric , zero, or NULL value	Uses the floating-point numbers with 16 or fewer significant digits
Integer	Int	Int	Numeric , zero, or NULL value	Stores whole numbers (no decimal point)
Nvarchar [(n | max)]	-	Nvarchar(*n*) or Nvarchar(max)	A character string, blank space (s) or NULL value	Variable-length Unicode character data. N can be a value from 1 through 4,000.

REFERENCES

The primary references related to this document are located on the OCC website:

- CCSG Data Guide
- eData
- eData Templates
- ICD10
- FAQ

SECTION 1. DATA TABLES 1A, 1B, AND 1C

1.1 DT1A – SENIOR LEADERSHIP

Create one record for each senior leader and use the following column names and definitions for clarity and uniformity:

TABLE 1-1: DT1A COLUMN DEFINITIONS

Column Name	SQL-Server Data Type	Definition
FY	Int YYYY	The fiscal year for which the Data Tables are being submitted; can be from October 1 of the prior year through September 30 of the year being funded. (*e.g.,* 2024)
GrantNumber	Varchar(25)	The grant application identification number (*e.g.*, 123456)
ReportingDate	DateTime MM/DD/YYYY	Center-defined reporting date
LastName	Varchar(25)	The last name of the senior leader
FirstName	Varchar(25)	The first name of the senior leader
MiddleName	Varchar(25)	The middle name or initial of the senior leader
isNew	Char(1)	Indicate whether this is a new leader since the last application was submitted; use “Y” for yes and “N” for no.
Title	Varchar(100)	The title of the senior leader
Degree	Varchar(15)	The academic degree(s) acronym or abbreviation of the senior leader (*e.g.*, MD, PhD)
Comments	Varchar(8000)	An optional free text field that allows users to enter notes or remarks on the current record.

A data table 1A format example can be found here: DT1A Format Example

1.2 DT1B – PROGRAMS, LEADERS, AND PROGRAM CODES

Create one record for each research program; use the following column names and definitions for clarity and uniformity.

For research programs with multiple leaders, please add seven additional fields per additional leader, for instance, LastNameN, FirstNameN, MiddleNameN, DegreeN1, DegreeN2, DegreeN3, isNewN. N is a numeric value that is greater than 1.

TABLE 1-1: DT1B COLUMN DEFINITIONS

Column Name	SQL-Server Data Type	Definition
FY	Int YYYY	The fiscal year for which the Data Tables are being submitted; it can be from October 1 of the prior year through September 30 of the year being funded. (*e.g.,* 2024)
GrantNumber	Varchar(25)	The grant application identification number (*e.g.*, 123456)
ReportingDate	DateTime MM/DD/YYYY	Center-defined reporting date
ProgCode	Varchar(5)	The alphanumeric code that identifies the clinical research program. This code is also defined in Data Tables 2 and 4 (e.g., 01, 02, XT, or BC)
ProgName	Varchar(255)	The name of the research program
NoOfMember	Int	The number of members assigned to the research program including program leader(s). Individuals belonging to multiple programs should be counted only once.
isNewProg	Char(1)	Indicate whether the research program listed is newly added since the last application submission by using 'Y' for yes and 'N' for no
isDevProg	Char(1)	Indicate whether the research program listed is supported by developmental funds; use ‘Y’ for yes and ‘N’ for no
isMultiLeader	Char(1)	Indicate whether the research program listed is managed by multiple leaders; use ‘Y’ for yes and ‘N’ for no
LastName	Varchar(25)	The last name of the research program leader
FirstName	Varchar(25)	The first name of the research program leader
MiddleName	Varchar(25)	The middle name of the research program leader
Degree	Varchar(15)	The academic degree(s) acronym or abbreviation of the first program leader (*e.g.*, MD, PhD)
isNewLeader	Char(1)	Indicate whether this is a new leader since the last application was submitted; use ‘Y’ for yes and ‘N’ for no.
LastName2	Varchar(25)	The last name of the secondary program leader
FirstName2	Varchar(25)	The first name of the secondary program leader
MiddleName2	Varchar(25)	The middle name of the secondary program leader
Degree2	Varchar(15)	The academic degree(s) acronym or abbreviation of the secondary leader (e.g., MD, PhD)

Column Name	SQL-Server Data Type	Definition
isMultiLeader2	Char(1)	Indicate whether this leader is newly added since the last application submission by using 'Y' for yes and 'N' for no
Comments	Varchar(8000)	An optional free text field that allows users to enter notes or remarks on the current record.

A data table 1B format example can be found: DT1B Format Example

1.3 DT1C – SHARED RESOURCES

Create one record for each shared resource and use the following column names and definitions for clarity and uniformity.

For shared resources with multiple leaders, please add seven additional fields per additional leader, for instance, LastNameN, FirstNameN, MiddleNameN, DegreeN1, DegreeN2, DegreeN3, isNewN. N is a numeric value that is greater than 1.

TABLE 1-1: DT1C COLUMN DEFINITIONS

Column Name	SQL-Server Data Type	Definition
FY	Int YYY Y	The fiscal year for which the Data Tables are being submitted; it can be from October 1 of the prior year through September 30 of the year being funded. (*e.g.,* 2024)
GrantNumber	Varchar(25)	The grant application identification number (*e.g.*, 123456)
ReportingDate	DateTime MM/DD/YYYY	Center-defined reporting date
SRName	Varchar(255)	The name of the shared resource
SRSubCat1	Float	A three-digit code to identify the shared resource subcategory (e.g., 1.37)
SRSubCat2	Float	A three-digit code to identify the shared resource subcategory (e.g., 2.10)
SRSubCat3	Float	A three-digit code to identify the shared resource subcategory (e.g., 7.04)
isNewSR	Char(1)	Indicate whether this shared resource is newly added since the last application submission by using 'Y' for yes and 'N' for no Note that shared resources are peer-reviewed components of the CCSG and thus cannot be added or removed during a non-competing (Type 5) year without prior approval from the NCI's Office of Cancer Centers (OCC). If your center is contemplating a modification to shared resources during a non-competing year, please reach out to your Program Officer for guidance
isDevSR	Char(1)	Indicate whether the shared resource listed is supported by developmental funds; use 'Y' for yes and 'N' for no
isMultiDirector	Char(1)	Indicate whether the shared resource listed is managed by multiple directors; use 'Y' for yes and 'N' for no

Column Name	SQL-Server Data Type	Definition
LastName	Varchar(25)	The last name of the primary shared resource director
FirstName	Varchar(25)	The first name of the primary shared resource director
MiddleName	Varchar(25)	The middle name of the primary shared resource director
Degree	Varchar(15)	The academic degree acronym or abbreviation of the primary director (e.g., MD, PhD)
isNewDirector	Char(1)	Indicate whether this director is newly added since the last application submission by using 'Y' for yes and 'N' for no
LastName2	Char(1)	The last name of the secondary shared resource director
FirstName2	Varchar(25)	The first name of the secondary shared resource director
MiddleName2	Varchar(25)	The middle name of the secondary shared resource director
Degree2	Varchar(15)	The academic(s) degree acronym or abbreviation of the secondary director (e.g., MD, PhD)
isNewDirector2	Char(1)	Indicate whether this director is newly added since the last application submission by using 'Y' for yes and 'N' for no
Comments	Varchar(8000)	An optional free text field that allows users to enter notes or remarks on the current record.

A data table 1C format example can be found here: DT1C Format Example

SECTION 2. DATA TABLES 2A AND 2B – ACTIVE FUNDED PROJECTS

2.1 DT2A – ACTIVE FUNDED PROJECTS

For a center-defined reporting date, create one record for each funded project and use the column names and definitions below.

For multi-PI or multi-investigator grants, please add three extra fields for each additional leader, for instance, LastNameN, FirstNameN, MiddleNameN, where N is a numeric value greater than 1.

TABLE 2-1: DT2A COLUMN DEFINITIONS

Column Name	SQL-Server Data Type	Definition
FY	Int YYYY	The fiscal year for which the Data Tables are being submitted; it can be from October 1 of the prior year through September 30 of the year being funded. (*e.g.,* 2024)
GrantNumber	Varchar(25)	The grant application identification number (*e.g.*, 123456)
ReportingDate	DateTime MM/DD/YYYY	Center-defined reporting date
LastName	Varchar(25)	The last name of the PI from your center who is responsible for this project

Column Name	SQL-Server Data Type	Definition
FirstName	Varchar(25)	The first name of the PI from your center who is responsible for this project
MiddleName	Varchar(25)	The middle name of the PI from your center who is responsible for this project
isMultiPI	Char(1)	Indicate whether this project is a multi-PI grant; use 'Y' for yes and 'N' for no. Note: According to NIH's definition (http://grants.nih.gov/grants/multi_pi/faq.htm#a1) multiple PIs have equal authority for the grant or contract and are jointly responsible for the scientific and technical direction of the project.
isMultiInvst	Char(1)	Indicate whether the project is a multi-investigator grant; use 'Y' for yes and 'N' for no. For Data Table 2A (DT2A), "multiple investigators" refer to the investigators of the sub-projects for grants such as SPORE, P50, P01, and so on. These investigators may not be recognized in the NIH grants system as PIs; however, we're still identifying them in DT2A.
isNewDirector2	Char(1)	Indicate whether this director is newly added since the last application submission by using 'Y' for yes and 'N' for no
isPeerRev	Char(1)	Indicate whether the projects are awarded by NCI, NIH, or organizations with peer-review funding systems as listed on the OCC website; use 'Y' for yes and 'N' for no.
isSubContract	Char(1)	Indicate whether the project is a subcontract; use 'Y' for yes and 'N' for no
FundingSource	Varchar(100)	Specify the financial sponsor for the project (e.g., NCI, ACS…)
ProjNo	Varchar(100)	Commonly referred to as the application number or grant number. This unique identification number for the grant is composed of the type code, activity code, Institute code, serial number, support year, and/or suffix code (e.g., 1R01CA059736-01)
ProjStartDate	DateTime MM/DD/YYYY	The official start date a grant award begins, which should be the start date of the first budget period (e.g., 6/1/2019).
ProjEndDate	DateTime MM/DD/YYYY	The official end date a grant award concludes, which should be the last date of the final budget period (e.g., 6/1/2024).

Column Name	SQL-Server Data Type	Definition
ProjTitle	Varchar(8000)	The official title of the research project being carried out at your institution (e.g., Regulation of mitochondrial inheritance in yeast)
AnnualProjDC	Int	Annual Costs that can be identified specifically with a particular sponsored project, or other institutional activity or that can be directly assigned to such activities relatively easily with a high degree of accuracy (e.g., 1560000) *Do not include special characters such as commas (,) and the currency symbol ($).*
CARelevantAnnualProjDC	Int	Using a method of the centers devising, estimate the cancer-relevant portion of a project and report the funding. Be prepared to defend this estimate in peer review. For grants that are 100% cancer-relevant (such as all NCI grants), this will be identical to the Annual Project Direct Costs.
CARelevantAnnualPercent	Int	The percentage assigned to the project based on the center's established method for determining the cancer relevance (e.g., 20,100). *Do not include special characters such as the percent sign (%)*
ProgCode	Varchar(15)	An alphanumeric code that identifies the research program affiliated with the clinical research study as defined by the center in Data Table 1B (e.g., 42, XY). Identify all training grants, including the F, K, and T series NIH grants, with the program code "T".
ProgPercent	Int	The percentage of research attributable to the identified research program (e.g., 20,100). *Do not include special characters such as the percent sign (%)*
AnnualProgDC	Int	Annual Direct Costs that support research carried out in the center's research programs (*e.g.*, 1560000) Do not include a comma (,) or a currency sign ($)
Comments	Varchar(8000)	An optional free text field that allows users to enter notes or remarks on the current record.

A data table 2A format example can be found: DT2A Format Example

2.2 DT2B – ACTIVE FUNDED PROJECTS

List the total number of projects and the sum of direct for each major funding agency category as follows: NCI Peer-Reviewed, Other NIH Peer-Reviewed, Other Peer-Reviewed; and Industry Non-Peer-Reviewed and Other Non-Peer Reviewed Projects.

TABLE 2-2: DT2B COLUMN DEFINITIONS

Column Name	SQL-Server Data Type	Definition
FY	Int YYYY	The fiscal year for which the Data Tables are being submitted; can be from October 1 of the prior year through September 30 of the year being funded. (*e.g.,* 2024)
GrantNumber	Varchar(25)	The grant application identification number (*e.g.*, 123456)
ReportingDate	DateTime MM/DD/YYYY	Center-defined reporting date
NCIPRTotalNo	Int	The total number of NCI Peer-Reviewed projects
NCIPRDC	Int	The direct cost amount of NCI Peer-Reviewed projects
OthNIHPRTotalNo	Int	The total number of NIH Peer-Reviewed projects
OthNIHPRDC	Int	The direct cost amount of NIH Peer-Reviewed projects
OthPRTotalNo	Int	Total number of other Peer-Reviewed projects
OthPRDC	Int	The direct cost amount of Other Peer-Reviewed projects
IndNonPRTotalNo	Int	The total number of Industry Non-Peer-Reviewed projects
IndNonPRDC	Int	The direct cost amount of Industry Non-Peer-Reviewed projects
OthNonPRTotalNo	Int	The total number of other Non-Peer-Reviewed projects
OthNonPRDC	Int	The direct cost amount of other Non-Peer-Reviewed projects
Comments	Varchar(8000)	An optional free text field that allows users to enter notes or remarks on the current record.

A data table 2B format example can be found: DT2B Format Example

SECTION 3. DT3 – NEWLY REGISTERED PATIENTS BY ANATOMIC CANCER SITE

For the 12 months defined by the cancer center, create one record for reportable cancers and use the following column names and definitions for clarity and uniformity.

Note to consortium cancer centers and cancer centers with affiliated institutions: Submit separate DT3 tables for each consortium partner and / or affiliated institution (*e.g.*, pediatric hospital) that is a formal component of the cancer center but maintains a separate cancer registry. Do not include loosely affiliated community partners.

TABLE 3: DT3 COLUMN DEFINITIONS

Column Name	SQL-Server Data Type	Definition
FY	Int YYYY	The fiscal year for which the Data Tables are being submitted; it can be from October 1 of the prior year through September 30 of the year being funded. (*e.g.,* 2024)
GrantNumber	Varchar(25)	The grant application identification number (*e.g.*, 123456)
ReportingSource	Varchar(255)	The name of the reporting source. For consortium centers or those affiliated with affiliated institutions, indicate the specific name of the reporting institution
ReportingStartDate	DateTime MM/DD/YYYY	The center-defined 12-month reporting start date
ReportingEndDate	DateTime MM/DD/YYYY	The center-defined 12-month reporting end date
PrimarySite	VarChar(255)	Reportable Cancers. Malignancies with an International Classification of Diseases for Oncology (ICD) behavior code of 2 or 3 should be reported, following the established requirements of registry standard-setting organizations. Please refer to the ICD Codes on the OCC website ICD10
NewlyRegisteredPatient	Int	Newly registered patients are those seen face-to-face and recorded in the Cancer Center's Cancer Registry for the first time for that diagnosis during the reporting period. They include inpatients and outpatients who: 1. are newly diagnosed and/or receiving the first course of treatment at the cancer center, i.e., equivalent to American College of Surgeons-defined analytic case codes 00 – 22 FORDS-2016 2. have recurrent or persistent disease and are referred to the cancer center for evaluation and treatment, i.e., equivalent to American College of Surgeons-defined non-analytic code 32.
Comments	Varchar(8000)	An optional free text field that allows users to enter notes or remarks on the current record.

A data table 3 format example can be found: DT3 Format Example

SECTION 4. DT4 INFORMATION ON CLINICAL RESEARCH STUDIES

Create one record for each clinical research study and use the column names and definitions below for clarity and uniformity.

TABLE 4: DT4 COLUMN DEFINITIONS

Column Name	SQL-Server Data Type	Definition
FY	Int YYYY	The annual period for which the Data Tables are being submitted; it can be from October 1 of the prior year through September 30 of the year being described. (*e.g.,* 2022)
GrantNumber	Varchar(25)	The P30 grant application identification number (*e.g.*, 123456)
ReportingStartDate	DateTime MM/DD/YYYY	The date on which the center-defined 12-month reporting period started
ReportingEndDate	DateTime MM/DD/YYYY	The date on which the center-defined 12-month reporting period ended
ClinicalResearchCat	Varchar(15)	The Clinical Research Category in which the clinical research or protocol is listed Valid entry: INT, OBS, or ANC/COR
StudySource	Char(1)	The category of the trial sponsor or Study Source Valid entry: N, E, I, or D N - National Cooperative group E - Externally Peer-Reviewed I - Institutional D - Industry
FundingSource	Varchar(100)	The specific name of the financial sponsor for the clinical research study. For institutionally sponsored trials or studies, list the name of the applicable funding agencies, (*e.g.*, NCI, NYU)
PrimarySite	Varchar(255)	The primary anatomic cancer site(s) (*i.e.*, breast, ovary) the clinical research study focuses on. If the clinical research study is broadly applicable to a number of potential anatomic sites, enter the term “multiple” in this column.
NCTID	Varchar(50)	The unique ID assigned to the trial by the National Clinical Trial program (ClinicalTrials.gov) for trials that have been submitted to ClinicalTrials.gov Protocol Registration System (PRS) previously. This ClinicalTrials.gov ID appears as "NCT" followed by 8 numeric characters (such as NCT12345678). (i.e., NCT00009876); If it is not applicable, use the ProtocolID.
NCIID	Varchar50)	The unique ID assigned to the trial by the CTRP.
ProtocolID	Varchar(50)	The unique identifier for the study. List the common protocol number that the trial is known under nationally, if one exists. For other trials that do not have an NCT number or a common protocol number that the trial is known under nationally, use an internal protocol identification or IRB number.
OthProtocolID	Varchar(50)	Additional IDs assigned to the trial, including the following: NCI, CTEP or DCP, unique IDs from other registries, Protocol numbers assigned by the review board, other IDs
LocalTrialID	Varchar50)	The unique ID assigned at the Cancer Center level and used at the sites level to identify a trial.

Column Name	SQL-Server Data Type	Definition
IsMultiInst	Char(1)	Indicate whether the study is multiple institutions; use “Y” for yes and “N” for no.
LastName	Varchar(25)	The last name of the Principal Investigator from your center who is responsible for this Clinical Research Study
FirstName	Varchar(25)	The first name or initial of the Principal Investigator from your center who is responsible for this Clinical Research Study Do not include a period (.)
MiddleName	Varchar(25)	The middle name or initial of the Principal Investigator from your center who is responsible for this Clinical Research Study Do not include a period (.)
ProgCode	Varchar(5)	An alphanumeric Program Code that identifies the Research Program affiliated with the clinical research study as defined by the center in Data Tables 1B and 2A. For clinical research studies that span more than one Research Program, include both Program Codes in this column. Refer to the Falls, R. example in the CCSG Data Guide
OpenDate	DateTime MM/DD/YYYY	The official start date of a trial at your center determined by 1) the date of activation noted in an official clinical trial activation announcement or 2) the date of first patient accrual if the trial in question did not have a formal activation announcement. This value on CTRP DT4 is determined by the earliest “open” status date at any site associated with the center on the trial. The following trial statuses reflect an “open” status in CTRP: Active, Enrolling by Invitation, Available, Temporarily Closed to Accrual or Temporarily Closed to Accrual and Intervention.
CloseDate	DateTime MM/DD/YYYY	The date the clinical research study closed to accrual. This does not include patient follow-up. If the study is still open, this field will be blank/null. This value on the CTRP-generated DT4 is determined by the latest “closed” date at any site associated with the cancer center on the trial. The following statuses reflect a “closed” status in CTRP: Closed to Accrual, Closed to Accrual and Intervention, Complete, Administratively Complete or Withdrawn.
Phase	Varchar(255)	Early Phase I: Exploratory trials, involving very limited human exposure, with no therapeutic or diagnostic intent (e.g., screening studies, microdose studies). See FDA guidance on exploratory IND studies for more information. I: Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients. I/II: Trials that are a combination of phases 1 and 2. II: Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in

Column Name	SQL-Server Data Type	Definition
		participants with the disease or condition under study and to determine the common short-term side effects and risks. II/III: Trials that are a combination of phases 2 and 3. III: Includes trials conducted after preliminary evidence suggesting the effectiveness of the drug has been obtained and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug. IV: Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use. N/A: Trials without phases (for example, studies of devices or behavioral interventions). Note: do not include blank spaces.
IsPilot	Char(1)	Pilot attribute can be assigned to any phase. Indicate whether the study is a pilot phase; use “Y” for yes and “N” for no.
PrimaryPurpose	Varchar(3)	The type or primary purpose of the clinical trial as follows: Tre: Treatment Pre: Prevention Sup: Supportive Care Scr: Screening Dia: Diagnostic Hsr: Health Services Research Bas: Basic Science Dev: Device Feasibility Oth: Other Valid entries: 'Tre', 'Pre', 'Sup', 'Scr', 'Dia', 'Hsr', 'Bas', 'Dev', or 'Oth'
Prag	Char(1)	Indicate whether the trail is pragmatic; use 'Y' for yes and 'N' for no. See the CCSG Data Guide for the definition.
OfficialTitle	Varchar(8000)	Official name of the protocol provided by the study principal investigator or sponsor (Limit: 600 characters or fewer).
EntireStudy	Int	The total targeted accrual for the entire study. For both single-site and multi-site trials initiated at your center, indicate the total number of participants needed for the entire study. For multi-site trials that your center participates in but did not initiate, leave this column empty. Do not submit a targeted range, such as “10 – 100.”
YourCenterTotal	Int	The targeted accrual for your center. For single-site and multi-site trials initiated at your center, indicate the total number of participants your center is expected to accrue for the study. Do not submit a targeted range, such as “10 – 100.”
Center12Mos	Int	Provide the number of participants accrued to this clinical research study during the identified 12-month reporting period study your cancer center and its formal consortium partners.
CenterToDate	Int	Provide the number of participants accrued to this clinical research study to date at your cancer center and its formal consortium partners. This number is a cumulative figure, not an annual total.

Column Name	SQL-Server Data Type	Definition
Other12Mos	Int	Provide the number of participants accrued to this clinical research study during the identified 12-month reporting period at all hospitals, treatment facilities, and/or research facilities that are a formal part of the cancer center (*e.g.*, nearby community hospitals).
OtherToDate	Int	Provide the number of participants accrued in the clinical research study to date at all hospitals, treatment facilities, and/or research facilities that are a formal part of the cancer center (*e.g.*, nearby community hospitals). This number is a cumulative figure, not an annual total.
EntireStudy AccrualToDate	Int	If the Lead Organization, column is populated with a summary of accrual for all participating sites on the trial through the last day of the reporting period (directly and not directly connected to the Lead Organization CTRP Family). If this is a participating site, leave this column blank.
Comments	Varchar(8000)	An optional free text field that allows users to enter notes or remarks on the current record.

A data table 4 format example can be found: DT4 Format Example

APPENDIX A. DATA TABLE FORMAT EXAMPLES

DT1A FORMAT EXAMPLE

Data Table 1A- Senior Leadership

FY	GrantNumber	ReportingDate	LastName	FirstName	MiddleName	IsNew	Title	Degree	Comments
2023	123456	01/01/2022	Sutton	Baylor	T	N	Director and Principal Investigator	MD, PhD	
2023	123456	01/01/2022	Marucco	Gina	Elizabeth	N	Deputy Director	PhD	
2023	123456	01/01/2022	Galley	Mark		N	Assoc. Director for Basic Science	MD	
2023	123456	01/01/2022	Barrie	Thomas	Ellen	Y	Assoc. Director for Clinical Research	MD, PhD, MS	
2023	123456	01/01/2022	Wong	Lee	Q.	N	Assoc. Director for Population Research	PhD	

DT1B FORMAT EXAMPLE

Data Table 1B – Program Leaders

FY	Grant Number	Reporting Date	Prog Code	Prog Name	NoOfMember	IsNewProg	IsDevProg	IsMultiLeader	Last Name	First Name	Middle Name	Degree	isNewLeader	Last Name	First Name	Middle Name	Degree2	IsNewLeader2	Comments
2023	123456	01/10/2022	01	Molecular and Cellular Biology	25				Harrington	Marc	F	MD, PhD							
2023	123456	01/10/2022	02	Cancer Control and Prevention	14	Y			Pham	Phuong	Duong	PhD							
2023	123456	01/10/2022	03	Epidemiology	19				Kaufman	Richard	W	MD, PhD							
2023	123456	01/10/2022	04	Developmental Therapeutics	15			Y	Wood	Mary		MD, PhD		Storm	John		PhD	Y	
2023	123456	01/10/2022	05	Women's Cancers	22				Miller	Barbara	Jasmine	PhD							
2023	123456	01/10/2022	CCG	Cell Cycle and Growth Control	12				Neuhauser	Beverly									
2023	123456	01/10/2022	IM	Immunology	27				Bhorjee	Jaswant	S	MD, PhD	Y						
2023	123456	01/10/2022	ZY	Non-Aligned Members	12														

Please note that certain columns are arranged vertically to fit on a single page for demonstration purposes only.

DT1C FORMAT EXAMPLE

Data Table 1C – Shared Resources

FY	Grant Number	Reporting Date	SRName	Sub Cat 1	Sub Cat 2	Sub Cat 3	IsNewSR	IsDevSR	IsMultiDirector	Last Name	First Name	Middle Name	Degree	IsNewDirector	Last Name2	First Name2	Middle Name2	Degree2	IsNewDirector2	Comments
2023	123456	01/10/2022	Biostatistics	6.01			N	N	N	Francini	Benjamin		PhD	Y						
2023	123456	01/10/2022	DNA Sequencing	1.22	1.35		N	N	N	Kelley	Steven		MD, PhD	N						
2023	123456	01/10/2022	Genomics and Proteomics	1.36			Y	N	N	Goldstein	Phillip		PhD	N						
2023	123456	01/10/2022	Bioinformatics	7.02			N	N	N	Mayrend	Jody	Kim	MD, PhD	N						
2023	123456	01/10/2022	Organic Synthesis	1.12			N	N	N	Singer	Richard		MD, PhD	Y						
2023	123456	01/10/2022	Transgenic Animal Facility	1.03	1.06	1.09	N	N	Y	Peterson	Douglas	John	MD	N	Barns	Nancy		MD	N	

Please note that certain columns are arranged vertically to fit on a single page for demonstration purposes only.

DT2A FORMAT EXAMPLE

2P30CA123456-09

Data Table 2A- Active Funded Projects

FY	GrantNumber	ReportingDate	Last Name	First Name	MiddleName	Last Name 2	First Name 2	MiddleName2	isMultiPI	isMultiInvest	isPeerRev	isSubContract	Funding Source	Proj No	ProjStartDate	ProjEndDate	Proj Title	AnnualProjDC	CARelevantPercent	CARelevantAnnualProjDC	ProgCode	ProgPercent	AnnualProgDC	Comments
2023	123456	03/01/2018	Alfred	Leon									NCI	1R01CA059736-01	06-01-2014	05-30-2023	Triterpenoids as chemo preventative agents Triterpenoids	200000	100	200000	4	100	2000000	
2023	123456	03/01/2018	Dubois	Yvette							Y		NCI	5R01CA067893-02	09-01-2012	08-03-2023	Star trial (Tamoxifen vs. Raloxifene)	100000	100	100000	1	60	60000	
2023	123456	03/01/2018	Dubois	Yvette							Y		NCI	5R01CA067893-02	09-01-2012	08-03-2023	Star trial (Tamoxifen vs. Raloxifene)				5	40	40000	
2023	123456	03/01/2018	Birmann	Brad		Glick	Darian		Y		Y		NINDS	1R01NS046045-03	03-01-2013	02-28-2018	Targeting the anti-apoptotic protein surviving in glioma	300000	100	300000	CB	100	300000	
2023	123456	03/01/2018	Bhorjee	Jacob		Vembu	Dana		Y		Y		NHLBI	1R01HL056899-01	05-01-2015	04-20-2030	Natural ligands of the aryl hydrocarbon receptor	400000	75	300000	MCB	50	150000	

FY	GrantNumber	ReportingDate	Last Name	First Name	MiddleName	Last Name 2	First Name 2	MiddleName2	isMultiPI	isMultiInvest	isPeerRev	isSubContract	Funding Source	Proj No	ProjStartDate	ProjEndDate	Proj Title	AnnualProjDC	CARelevantPercent	CARelevantAnnualProjDC	ProgCode	ProgPercent	AnnualProgDC	Comments
2023	123456	03/01/2018							Y		Y		NHLBI	1R01HL056899-01	05-01-2015	04-20-2030	Natural ligands of the aryl hydrocarbon receptor				ET	50	150000	
2023	123456	03/01/2018	Michaels	Helen		Herman	Beth		Y		Y		NCI	2R01CA876-098-02	12-01-2013	11-30-2018	Southern Community Cohort	300000	100	300000	EPI	100	300000	
2023	123456	03/01/2018	Donegan	Alex							Y	Y	NHLBI Dartmouth	3R01HL08685-03S2	08-01-2012	07-03-2023	Calpain and p120 catenin regulation of cadherin function	50000	100	50000	3	100	50000	
2023	123456	03/01/2018	Wang	Thomas							Y	Y	NCI	3R01CA07196-03	08-01-2012	07-30-2023	Southern Community Cohort	775000	100	775000	3	100	775000	
2023	123456	03/01/2018	Persky	Dawn							Y		NCI	S1001	07-18-2011	06-30-2014	A Phase II Trial of R-Chop followed by Yttrium-90 Ibritumomab tiuxetan for Early Stage Diffuse Large B-cell Lymphoma	215000	100	215000	5	100	215000	
2023	123456	03/01/2018	Lee	Rich						Y	Y		NCI	5P50CA119997-04	03-01-2012	02-28-2023	SPORE in Lung Cancer	1250000	100	1250000				

FY	GrantNumber	ReportingDate	Last Name	First Name	MiddleName	Last Name 2	First Name 2	MiddleName2	isMultiPI	isMultiInvest	isPeerRev	isSubContract	Funding Source	Proj No	ProjStartDate	ProjEndDate	Proj Title	AnnualProjDC	CARelevantPercent	CARelevantAnnualProjDC	ProgCode	ProgPercent	AnnualProgDC	Comments
2023	123456	03/01/2018	Lee	Rich						Y	Y		NCI	5P50CA119997-04	03-01-2012	02-28-2023	SPORE in Lung Cancer Project 1: Anti-tumor Mechanisms of SRC Inhibitors in Lung Cancer				2	100	250000	
2023	123456	03/01/2018	Lee	Rich						Y	Y		NCI	5P50CA119997-04	03-01-2012	02-28-2023	SPORE in Lung Cancer Core C: Administration and Patient Advocacy		100	40000	ZY	100		
2023	123456	03/01/2018	Uriel	Grant						Y	Y			5P50CA119997-04										
2023	123456	03/01/2018	Lee	Rich						Y	Y		NCI	5P50CA119997-04	03-01-2012	02-28-2023	SPORE in Lung Cancer: Core A: Tissue Procurement, Pathology, and Bioinformatics		100	300000	ZY	100		
2023	123456	03/01/2018	Jackson	Abraham						Y	Y			5P50CA119997-04										
2023	123456	03/01/2018	Lee	Rich						Y	Y		NCI	5P50CA119997-04	03-01-2012	02-28-2023	SPORE in Lung Cancer Project 2: E2F's Impact on Therapeutic Efficacy				1	100	200000	

FY	GrantNumber	ReportingDate	Last Name	First Name	MiddleName	Last Name 2	First Name 2	MiddleName2	isMultiPI	isMultiInvest	isPeerRev	isSubContract	Funding Source	Proj No	ProjStartDate	ProjEndDate	Proj Title	AnnualProjDC	CARelevantPercent	CARelevantAnnualProjDC	ProgCode	ProgPercent	AnnualProgDC	Comments
2023	123456	03/01/2018	Sherman	William						Y	Y			5P50CA119997-04										
2023	123456	03/01/2018	Smith	Ellen						Y	Y			5P50CA119997-04										
2023	123456	03/01/2018	Lee	Rich						Y	Y		NCI	5P50CA119997-04	03-01-2012	02-28-2023	SPORE in Lung Cancer: Project 3: RRM1 in the Management of Lung Cancer				1	100	360000	
2023	123456	03/01/2018	Stuart	James						Y	Y			5P50CA119997-04										
2023	123456	03/01/2018	Pope	Beatrice									Vical	NA	07-01-2014	12-21-2016	Phase II Trial of Allovectin-7 for Metastatic Melanoma	250000			4	100	250000	

Please note that certain columns are arranged vertically to fit on a single page for demonstration purposes only.

DT2B - FORMAT EXAMPLE

2P30CA123456-09

Data Table 2B – Active Funded Projects

FY	P30Grant Number	Reporting Date	NCIPRTotalNo	NCIPR DC	OthNIHPRTotalNo	OthNIHPR DC	OthPRTotalNo	OthPR DC	IndNonPRTotalNo	Ind NonPR DC	OthNonPRTotalNo	Oth NonPR DC	Comments
2023	2P30CA123456-09	01/01/2022	13	5180000	9	1916000	5	2377000	2	325000	4	1706900	

Please note that certain columns are arranged vertically to fit on a single page for demonstration purposes only.

DT3 - FORMAT EXAMPLE

DT3 - Newly Registered Patients by Anatomic Cancer Site

FY	Grant Number	Reporting Source	Reporting StartDate	Reporting EndDate	PrimarySite	NewlyRegistered Patients	Comments
2023	123456	My Cancer Center	1/1/2022	12/31/2022	Lip, Oral Cavity and Pharynx	85	
2023	123456	My Cancer Center	1/1/2022	12/31/2022	Esophagus	62	
2023	123456	My Cancer Center	1/1/2022	12/31/2022	Stomach	181	
2023	123456	My Cancer Center	1/1/2022	12/31/2022	Small Intestine	0	
2023	123456	My Cancer Center	1/1/2022	12/31/2022	Colon	728	
2023	123456	My Cancer Center	1/1/2022	12/31/2022	Rectum	50	
2023	123456	My Cancer Center	1/1/2022	12/31/2022	Anus	9	
2023	123456	My Cancer Center	1/1/2022	12/31/2022	Liver	121	
2023	123456	My Cancer Center	1/1/2022	12/31/2022	Pancreas	52	
2023	123456	My Cancer Center	1/1/2022	12/31/2022	Other Digestive Organ	174	
2023	123456	My Cancer Center	1/1/2022	12/31/2022	Larynx	50	
2023	123456	My Cancer Center	1/1/2022	12/31/2022	Lung	1257	
2023	123456	My Cancer Center	1/1/2022	12/31/2022	Other Respiratory and Intrathoracic Organs	105	
2023	123456	My Cancer Center	1/1/2022	12/31/2022	Bones and Joints	25	
2023	123456	My Cancer Center	1/1/2022	12/31/2022	Soft Tissue	35	
2023	123456	My Cancer Center	1/1/2022	12/31/2022	Melanoma, skin	81	
2023	123456	My Cancer Center	1/1/2022	12/31/2022	Kaposi’s sarcoma	21	
2023	123456	My Cancer Center	1/1/2022	12/31/2022	Mycosis Fungoides	23	
2023	123456	My Cancer Center	1/1/2022	12/31/2022	Other Skin	6	
2023	123456	My Cancer Center	1/1/2022	12/31/2022	Breast	1203	
2023	123456	My Cancer Center	1/1/2022	12/31/2022	Cervix	60	
2023	123456	My Cancer Center	1/1/2022	12/31/2022	Corpus Uteri	602	
2023	123456	My Cancer Center	1/1/2022	12/31/2022	Ovary	49	
2023	123456	My Cancer Center	1/1/2022	12/31/2022	Other Female Genital	33	
2023	123456	My Cancer Center	1/1/2022	12/31/2022	Prostate	382	
2023	123456	My Cancer Center	1/1/2022	12/31/2022	Other Male Genital	22	
2023	123456	My Cancer Center	1/1/2022	12/31/2022	Bladder	188	
2023	123456	My Cancer Center	1/1/2022	12/31/2022	Kidney	183	

FY	Grant Number	Reporting Source	Reporting StartDate	Reporting EndDate	PrimarySite	NewlyRegistered Patients	Comments
2023	123456	My Cancer Center	1/1/2022	12/31/2022	Other Urinary	10	
2023	123456	My Cancer Center	1/1/2022	12/31/2022	Eye and Orbit	6	
2023	123456	My Cancer Center	1/1/2022	12/31/2022	Brain & Nervous System	932	
2023	123456	My Cancer Center	1/1/2022	12/31/2022	Thyroid	188	
2023	123456	My Cancer Center	1/1/2022	12/31/2022	Other Endocrine System	21	
2023	123456	My Cancer Center	1/1/2022	12/31/2022	Non-Hodgkin's Lymphoma	190	
2023	123456	My Cancer Center	1/1/2022	12/31/2022	Hodgkin's Lymphoma	10	
2023	123456	My Cancer Center	1/1/2022	12/31/2022	Multiple Myeloma	307	
2023	123456	My Cancer Center	1/1/2022	12/31/2022	Lymphoid Leukemia	37	
2023	123456	My Cancer Center	1/1/2022	12/31/2022	Myeloid and Monocytic Leukemia	154	
2023	123456	My Cancer Center	1/1/2022	12/31/2022	Leukemia, other	1	
2023	123456	My Cancer Center	1/1/2022	12/31/2022	Other Hematopoietic	83	
2023	123456	My Cancer Center	1/1/2022	12/31/2022	Unknown Sites	118	
2023	123456	My Cancer Center	1/1/2022	12/31/2022	Ill-Defined Sites	3	

Please use the predefined Primary Site categories provided. Altering the list may reduce efficiency during data processing.

DT4 FORMAT EXAMPLE

Data Table 4- Clinical Research Protocols

FY	GrantNumber	ReportingStartDate	ReportingEndDate	ClinicalResearchCat	StudySource	Funding Source	Primary Site	NCT Number	Protocol ID	IsMultiInst	Last Name	First Name	Middle Name	ProgCode	OpenDate	CloseDate	Phase	PrimaryPurpose	OfficialTitle	EntireStudy	YourCenterTotal	Center12mos	CenterToDate	Other12mos	OtherToDate	EntireStudyAccuralToDate	Comments
2023	123456	01/01/2022	12/31/2022	INT	N	SWOG	Bladder	NCT00123407 12	SWOG-0712	Y	Armstrong	C	John	2	8/15/2013		III	Tre	Randomized chemo/rt/surg for bladder cancer		220	82	120				
2023	123456	01/01/2022	12/31/2022	INT	N	Alliance	Myeloid leukemia	NCT01060 3678	10603	Y	Kane	Steve		8	4/21/2012		III	Tre	Induction & Consolidation Chemo + Midostaurin v Placebo in Newly Diagnosed FLT3 Mutated AML		70	28	49				

FY	GrantNumber	ReportingStartDate	ReportingEndDate	ClinicalResearchCat	StudySource	Funding Source	Primary Site	NCT Number	Protocol ID	IsMultiInst	Last Name	First Name	Middle Name	ProgCode	OpenDate	CloseDate	Phase	PrimaryPurpose	OfficialTitle	EntireStudy	YourCenterTotal	Center12mos	CenterToDate	Other12mos	OtherToDate	EntireStudyAccuralToDate	Comments
2023	123456	01/01/2022	12/31/2022	INT	N	COG	Myeloid leukemia	NCT08123456	COG-08H9	Y	Lehr	D		4	5/1/2012		I	Tre	Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia		6	0	4				
2023	123456	01/01/2022	12/31/2022	INT	E	NYU, NCI	Multiple	NCT00110912	NCI-1109	Y	Mack	Frank	D	3	8/1/2012		III	Sup	Preparatory Aid to Improve Decision Making about Cancer Clinical Trials (PRE-ACT)	500	60	22	46	70	240	535	
2023	123456	01/01/2022	12/31/2022	INT	E	NCI	Colon, Rectum	NCT00068018	NCI 06-8-01	N	Shephard	A		2	12/5/2014		II	Pre	Polyethylene Glycol for ACF Reduction and Biomarker Modulation in Individuals with CRC Risk	140	140	34	68			184	

FY	GrantNumber	ReportingStartDate	ReportingEndDate	ClinicalResearchCat	StudySource	Funding Source	Primary Site	NCT Number	Protocol ID	IsMultiInst	Last Name	First Name	Middle Name	ProgCode	OpenDate	CloseDate	Phase	PrimaryPurpose	OfficialTitle	EntireStudy	YourCenterTotal	Center12mos	CenterToDate	Other12mos	OtherToDate	EntireStudyAccuralToDate	Comments
2023	123456	01/01/2022	12/31/2022	INT	I	NYU	Breast	NCT00001054	NYU-1054	N	Allen	Thomas		2	2/14/2013		I/II	Sup	Dose Finding and Tolerability ALA in Paclitaxel Induced Neuropathy Pts.	30	30	4	10			56	
2023	123456	01/01/202	12/31/202	INT	I	NYU	Lymphoma	NCT98765159	NYU-5150	N	Bates	S		4	5/1/2012		I	Tre	Ofatumumab for inindolent B-cell lymphomas		6	0	4				
2023	123456	01/01/2022	12/31/2022	INT	I	NYU	Multiple	NCT00981133	NYU-1133	Y	Dunn	R	Cherel	1	7/4/2015		II	Pre	Restasis Vs Placebo in Primary Prevention of Ocular GVHD	62	6	2	5	2	8	61	

FY	GrantNumber	ReportingStartDate	ReportingEndDate	ClinicalResearchCat	StudySource	Funding Source	Primary Site	NCT Number	Protocol ID	IsMultiInst	Last Name	First Name	Middle Name	ProgCode	OpenDate	CloseDate	Phase	PrimaryPurpose	OfficialTitle	EntireStudy	YourCenterTotal	Center12mos	CenterToDate	Other12mos	OtherToDate	EntireStudyAccrualToDate	Comments
2023	123456	01/01/2022	12/31/2022	INT	I	NYU	Multiple	NCT00120521	NU-0521	N	Hook	S		10	1/17/2013		II	Sup	Etanercept in Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor SCT	405	105	10	30			398	
2023	123456	01/01/2022	12/31/2022	INT	D	GSK	Leukemia	NCT00110806	GSK0806	N	Day	Patricia		10	3/1/2013		I	Sup	Phase 1 Trial of Palifermin for Oral Mucositis	85	15	6	8			34	
2023	123456	01/01/2022	12/31/2022	INT	D	BMS	Lymphoid leukemia	NCT00985013	DRUG-5013	N	Head	R		8	5/1/2014		III	Tre	Lenalidomide as Maintenance Therapy for Patients with B-cell CLL		113	47	79				

FY	GrantNumber	ReportingStartDate	ReportingEndDate	ClinicalResearchCat	StudySource	Funding Source	Primary Site	NCT Number	Protocol ID	IsMultiInst	Last Name	First Name	Middle Name	ProgCode	OpenDate	CloseDate	Phase	PrimaryPurpose	OfficialTitle	EntireStudy	YourCenterTotal	Center12mos	CenterToDate	Other12mos	OtherToDate	EntireStudyAccuralToDate	Comments
2023	123456	01/01/2022	12/31/2022	OBS	E	NCI	Brain and Nervous System	NCT01152909	NCI-2902	N	Falls	R	D	8 & 10	7/2/2012		N/A	Oth	Neurocognitive outcomes in pediatric brain tumor survivors following proton beam XRT vs conventional XRT	400	100	13	30			98	
2023	123456	01/01/2022	12/31/2022	OBS	E	American Cancer Society	Prostate	NCT01152152	ACS-2162	Y	Rogers	Seldon		6	9/5/2014		N/A	Oth	Focus group evaluation of prostate cancer symptom management education materials	80	14	6	8	7	14	62	
2023	123456	01/01/202	12/31/202	OBS	E	NCI	Ovarian	NCT01153315	NCI-3315	N	Lemon	J	Joseph	3	6/1/2013		N/A	Oth	Exogenous hormone use and risk of ovarian cancer		50	12	49				

FY	GrantNumber	ReportingStartDate	ReportingEndDate	ClinicalResearchCat	StudySource	Funding Source	Primary Site	NCT Number	Protocol ID	IsMultiInst	Last Name	First Name	Middle Name	ProgCode	OpenDate	CloseDate	Phase	PrimaryPurpose	OfficialTitle	EntireStudy	YourCenterTotal	Center12mos	CenterToDate	Other12mos	OtherToDate	EntireStudyAccuralToDate	Comments
2023	123456	01/01/2022	12/31/2022	OBS	I	NYU	Multiple	NCT01151926	NYU-1926	Y	Berry	June		08	5/1/2015		N/A	Oth	Risk factors for childhood cancer and hematological disorders by case- control studies	4000	1500	125	499	86	600	2200	
2023	123456	01/01/2022	12/31/2022	OBS	I	NYU, NIH	Multiple Myeloma	NCT01151007	NYU-1007	N	Smith	S		08	1/1/2010	4/7/2011	N/A	Oth	Treatment Decision Making in Older Adults Newly Diagnosed with MM		20	6	18				
2023	123456	01/01/2022	12/31/2022	ANC/COR	I	NYU	Brain	NCT01051762	NYU-1762	N	Okra	Selby		08	2/23/2016		N/A	Bas	Phase I & 2 drug metabolism polymorphisms & outcome in children with medulloblastoma	202	54	10	36			82	

FY	GrantNumber	ReportingStartDate	ReportingEndDate	ClinicalResearchCat	StudySource	Funding Source	Primary Site	NCT Number	Protocol ID	IsMultiInst	Last Name	First Name	Middle Name	ProgCode	OpenDate	CloseDate	Phase	PrimaryPurpose	OfficialTitle	EntireStudy	YourCenterTotal	Center12mos	CenterToDate	Other12mos	OtherToDate	EntireStudyAccuralToDate	Comments
2023	123456	01/01/2022	12/31/2022	ANC/COR	I	NYU	Leukemia	NCT01052701	NYU-2701	Y	Granger	I		08	6/15/2010		N/A	Bas	Prospective observational trial of telomere length and telomerase mutations in pediatric AML	100	30	12	25	8	18	74	
2023	123456	01/01/2022	12/31/2022	ANC/COR	I	NYU	Leukemia	NCT01050631	NYU-0631	N	Down	R	R	08	2/30/2014		III	Oth	Comparison of Acute and Long-term Toxicities in BM Donors w/wout G-CSF Treatment Prior to Harvest		206	48	89				

FY	GrantNumber	ReportingStartDate	ReportingEndDate	ClinicalResearchCat	StudySource	Funding Source	Primary Site	NCT Number	Protocol ID	IsMultiInst	Last Name	First Name	Middle Name	ProgCode	OpenDate	CloseDate	Phase	PrimaryPurpose	OfficialTitle	EntireStudy	YourCenterTotal	Center12mos	CenterToDate	Other12mos	OtherToDate	EntireStudyAccuralToDate	Comments
2023	123456	01/01/2022	12/31/2022	ANC/COR	I	NYU	Other hemapoietic	NCT01050890	NYU-0898	N	Gosden,	Robert		08	2/4/2015		N/A	Bas	Biology Study of Transient Myeloproliferative Disorder (TMD) in Children with Down Syndrome (DS)		17	1	3				

Please note that certain columns are arranged vertically to fit on a single page for demonstration purposes only.

APPENDIX B. SUMMARY OF CHANGES TO EDATA

Table B-1: Summary of Changes to eData

Updated Date	Effected Data Table(s)	Description of Changes
04/16/2025	DT2A	Added “CARelevantPercent” column.
06/06/2024	DT1	Consolidated academic degrees into one column.
04/30/2024		Reformatted the document and updated the minor versioning number from v3.1.3 to v3.1.4.
04/01/2023	DT4	Added a new column “Prag”
08/24/2022	DT3	Fixed broken links to ICD10 and FORDS-2016 in DT3.
02/05/2010	Introduction DT4	Modified Figure 1: The Data Tables Data Flow Diagram Modified the definition of the OpenDate and CloseDate, added EntireStudyAccrualToDate fields, and modified DT4 Example Format in the Appendix A, page A9-A13.
02/14/2018	DT4	To further harmonize fields and definitions with the ClinincalTrials.gov and CTRP: Renamed NCINumber to NCIID and modified the definition, modified Phase eliminating phase “0”, “Pilot”, and “Feasibility” options, modified the definition of the ProtocolID, Other12Mos, and OtherToDate, added “Dev” option to the Primary Purpose, added IsPilot, OtherProtocolID , NCIID, and Local Trial ID fields.
01/24/2023	DT1	Revised 1B “NoOfMember” column definition, eliminated 1C – Program Members, and labeled 1D as 1C.
	DT2	Eliminated total costs
	DT2A and DT2B	Moved all training projects to Cancer Research Career Enhancement and Related Activities. 39
	DT3	Eliminated “Patients newly accrued to treatment trials”, and combined “Female Breast” and “Male Breast” to “Breast”.
	DT4	No changes – CTRP will generate DT4 in the future (2018 or later).